Late onset chronic mucocutaneous candidiasis with lymphoma and specific serum inhibitory factor.
A patient with late onset chronic mucocutaneous candidiasis developed lymphocytic lymphoma. A specific inhibitor of in vitro lymphoproliferative responses to candidal antigen was detected in her serum which persisted following clinical remission of candidiasis after combined amphotericin-B and 5-Fluorocystosine therapy. It is unclear whether the combined therapy was exclusively anticandidal, nonspecific immunostimulant or cytotoxic affecting the underlying incipient lymphoma.
D000666:Amphotericin B / Q000627:therapeutic use; D000908:Antibodies, Fungal; D000946:Antigens, Fungal / Q000008:administration & dosage; D001667:Binding, Competitive; D002180:Candidiasis, Oral / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D005260:Female; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans; D007109:Immunity; D007165:Immunosuppression Therapy; D066298:In Vitro Techniques; D008213:Lymphocyte Activation; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000276:immunology; D008875:Middle Aged
D000908:Antibodies, Fungal; D000946:Antigens, Fungal; D000666:Amphotericin B; D005437:Flucytosine